The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC, April 13, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the…

Source

Previous articleMindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium
Next articleCybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules